Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 10/20 | 0.47 |
| ▸ | PTGES | O14684 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2089557 | 0.83 | NPC1 (0.59) | NPC1RAB9ANR5A1LTA4HGAA | |
| SCHEMBL10465844 | 0.82 | MAPT (0.56) | NPC1GAAL3MBTL1TSHR | |
| SCHEMBL5948125 | 0.81 | NPC1 (0.58) | NPC1RAB9ANR5A1FAAHTP53 | |
| SCHEMBL10563388 | 0.81 | NPC1 (0.58) | NPC1RAB9ANR5A1FAAHTP53 | |
| SCHEMBL8006745 | 0.81 | NPC1 (0.58) | NPC1RAB9ANR5A1FAAHTP53 | |
| SCHEMBL2200281 | 0.81 | NPC1 (0.58) | NPC1RAB9ANR5A1FAAHTP53 | |
| SCHEMBL7525722 | 0.81 | NPC1 (0.58) | NPC1RAB9ANR5A1FAAHTP53 | |
| SCHEMBL2089955 | 0.81 | NPC1 (0.58) | NPC1RAB9ANR5A1FAAHTP53 | |
| SCHEMBL8957600 | 0.81 | NPC1 (0.58) | NPC1RAB9ANR5A1FAAHTP53 | |
| SCHEMBL8324472 | 0.80 | NPC1 (0.64) | NPC1RAB9ANR5A1LTA4HGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130231334-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT APHIDS | SYNGENTA CROP PROTECTION LLC (US) | 2013-09-05 | — | — | US | disclosed |
| EP-2563118-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT APHIDS | Syngenta Participations AG (CH) | 2013-03-06 | — | — | EP | disclosed |
| WO-2011134819-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT APHIDS | SYNGENTA PARTICIPATIONS AG (CH) | 2011-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130231334-A1 | METHODS OF CONTROLLING NEONICOTINOID RESISTANT APHIDS | DDT, AGO2, INF2 | NPC1 2554/4885RAB9A 994/4885NR5A1 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.